- Home
- MTEK vs AIMD Comparison
MTEK vs AIMD Comparison
Compare MTEK & AIMD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MTEK
- AIMD
- Stock Information
- Founded
- MTEK 2008
- AIMD 1984
- Country
- MTEK Israel
- AIMD United States
- Employees
- MTEK N/A
- AIMD N/A
- Industry
- MTEK
- AIMD Biotechnology: Pharmaceutical Preparations
- Sector
- MTEK
- AIMD Health Care
- Exchange
- MTEK Nasdaq
- AIMD Nasdaq
- Market Cap
- MTEK 15.1M
- AIMD 16.9M
- IPO Year
- MTEK 2022
- AIMD N/A
- Fundamental
- Price
- MTEK $1.33
- AIMD $2.65
- Analyst Decision
- MTEK
- AIMD
- Analyst Count
- MTEK 0
- AIMD 0
- Target Price
- MTEK N/A
- AIMD N/A
- AVG Volume (30 Days)
- MTEK 67.6K
- AIMD 42.7K
- Earning Date
- MTEK 09-26-2025
- AIMD 11-14-2025
- Dividend Yield
- MTEK N/A
- AIMD N/A
- EPS Growth
- MTEK N/A
- AIMD N/A
- EPS
- MTEK N/A
- AIMD N/A
- Revenue
- MTEK $3,375,716.00
- AIMD $110,870.00
- Revenue This Year
- MTEK N/A
- AIMD N/A
- Revenue Next Year
- MTEK N/A
- AIMD N/A
- P/E Ratio
- MTEK N/A
- AIMD N/A
- Revenue Growth
- MTEK N/A
- AIMD 70.25
- 52 Week Low
- MTEK $1.31
- AIMD $2.00
- 52 Week High
- MTEK $6.47
- AIMD $5.00
- Technical
- Relative Strength Index (RSI)
- MTEK 28.07
- AIMD 26.81
- Support Level
- MTEK $1.63
- AIMD $3.20
- Resistance Level
- MTEK $1.80
- AIMD $3.43
- Average True Range (ATR)
- MTEK 0.14
- AIMD 0.23
- MACD
- MTEK -0.01
- AIMD -0.11
- Stochastic Oscillator
- MTEK 6.22
- AIMD 5.14
About MTEK Maris-Tech Ltd.
Maris Tech Ltd is a business-to-business approach, or B2B provider of remote video, audio, telemetry acquisition, distribution, and sharing solutions and products, using high-end digital video, audio, and wireless communication technologies. It designs, develops, manufactures and commercially sells miniature intelligent video and audio surveillance and communication systems, which are offered as products and solutions for the professional as well as the civilian and home security markets.
About AIMD Ainos Inc.
Ainos Inc is engaged in developing biologics for the treatment of human and animal diseases. The company mainly focuses on the research of the treatment of human disease indications, particularly influenza, hepatitis C, thrombocytopenia, and other indications using natural human interferon-alpha that is administered in a proprietary low-dose oral form. Its product pipeline includes VELDONA Pet cytoprotein supplements for pets, VELDONA human therapeutics for clinical use, and telehealth-friendly POCTs powered by the AI Nose technology platform.